Porphyrin Or Derivative Thereof Patents (Class 424/9.61)
  • Patent number: 7704489
    Abstract: A nanotagged chemical structure comprising a chemical structure with an associated photocatalyst and a tagging nanoparticle (a nanotag) grown in proximity to the photocatalyst, and a method for making the nanotagged chemical structure. The nanoparticle is grown in proximity to the photocatalyst by using a photocatalytic reduction reaction.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: April 27, 2010
    Assignee: Sandia Corporation
    Inventors: John A. Shelnutt, Craig J. Medforth, Yujiang Song
  • Patent number: 7682603
    Abstract: The instant invention concerns compositions comprising polymersomes, visible or near infrared emissive agents, and optionally a targeting moiety associated with a surface of the polymersome. The invention also relates to use of these compositions in the treatment of disease and in imaging methodology.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: March 23, 2010
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Daniel A. Hammer, Michael J. Therien, Paiman Peter Ghoroghchian
  • Patent number: 7659301
    Abstract: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: February 9, 2010
    Assignee: The General Hospital Corporation
    Inventors: Richard Rox Anderson, Bernhard Ortel, Edwin K. Joe
  • Publication number: 20090297456
    Abstract: Porphyrinic compounds that contain solubilizing groups are described, along with methods of making and using the same and compositions comprising such compounds. Examples of such compounds include compounds of Formula (I) wherein: Z is a porphyrinic macrocyclic, Alk1 and Alk2 are each independently an alkylidene chain; L is a linking group or is absent; R1 is preferably an ionic group or polar group; R2 is an ionic group, polar group, bioconjugatable group, or targeting group: R3 is present or absent and when present is a halo group, bioconjugatable group, or targeting group, n is O or 1 (that is, the CH group is present, or Alk1 and Alk2 are bonded directly to a carbon of the porphyrinic macrocycle Z); or a salt thereof.
    Type: Application
    Filed: October 19, 2006
    Publication date: December 3, 2009
    Inventors: K. Eszter Borbas, Jonathan S. Lindsey
  • Publication number: 20090191130
    Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
    Type: Application
    Filed: March 27, 2009
    Publication date: July 30, 2009
    Inventors: Han-Je Kim, Jonathan S. Lindsey
  • Patent number: 7560110
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: July 14, 2009
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, William J. McBride
  • Publication number: 20090162289
    Abstract: A tetrapyrollic photosensitizer compound having at least one pendant —CH2CH2CON(CH2CON(CH2COOH)2)2 or —N(CH2COOH)2 group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
    Type: Application
    Filed: February 19, 2009
    Publication date: June 25, 2009
    Applicant: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Amy Gryshuk, Lalit Goswami, William Potter, Allan Oseroff
  • Patent number: 7537751
    Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: May 26, 2009
    Assignee: Enzo Life Science, Inc.
    Inventors: Jannis G. Stavrianopoulos, Elazar Rabbani
  • Publication number: 20090117053
    Abstract: In accordance with an aspect of the present invention, a 5-aminolevulinic-acid-based compound (ALA-based compound) is delivered locally to a tissue or organ within a subject's body. In another aspect, a method of diagnosis or treatment is provided which comprises: (a) locally delivering an ALA-based compound to a tissue or organ within a subject's body and (b) illuminating the tissue or organ with light having a wavelength suitable to induce fluorescence of protoporphyrin IX (PPIX). In some embodiments, a local therapeutic agent is delivered to the targeted tissue or organ for treatment. In another aspect, formulations containing the ALA-based compound are provided.
    Type: Application
    Filed: November 6, 2008
    Publication date: May 7, 2009
    Applicant: Boston Scientific Scimed, Inc.
    Inventor: Jianmin Li
  • Publication number: 20090041672
    Abstract: A novel drug for treating a vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation which is efficacious in treating a vascular lesion in the deep part of the skin or the subcutaneous soft tissue caused by light irradiation without destroying normal cells on the skin surface and yet requires only a short shading time after the treatment. This drug for treating a vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation contains, as the active ingredient, mono-L-aspartyl chlorin e6, mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: April 14, 2006
    Publication date: February 12, 2009
    Inventors: Takafumi Ohshiro, Toshio Ohshiro
  • Publication number: 20090016965
    Abstract: Methods using internal image antibodies for photodiagnosis and/or phototherapy. The internal image antibodies are conjugated with a photoactive molecule such as a dye or photosensitizer, to target specific regions, such as biological receptors. The photoactive molecules are then activated for diagnosis or therapy. Advantageously, the internal image antibody is specific for a biological receptor, but does not require isolation of the receptor to prepare the antibody, and provides the desired specificity and selectivity for targeted diagnosis or therapy.
    Type: Application
    Filed: July 31, 2008
    Publication date: January 15, 2009
    Inventors: Raghaven Ragajopalan, Joseph E. Bugaj, Samuel I. Achilefu, Richard B. Dorshow
  • Patent number: 7371742
    Abstract: This invention relates to porphyrin compounds used to destroy or impair the functioning of a target biological material in photodynamic therapy, in particular against virus, tumoral cells, bacteria, tumorous tissues. The invention also relates to compositions containing such compounds and to a method in vitro to photosensitize detroy or impair the functioning of such target biological material.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: May 13, 2008
    Assignees: Institut Curie, Centre National de la Recherche Scientifique (CNRS)
    Inventors: David Grierson, Philippe Maillard, Bernard Loock, Telmo Figueiredo, Alain Croisy, Danielle Carrez
  • Patent number: 7348361
    Abstract: The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: March 25, 2008
    Assignee: Ecole Polytechnique Federale de Lausanne
    Inventors: Alexandre Marti, Norbert Lange, Matthieu Zellweger, Georges Wagnieres, Hubert Van Den Bergh, Patrice Jichlinski, Pavel Kucera
  • Patent number: 7320786
    Abstract: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: January 22, 2008
    Assignee: Light Sciences Oncology, Inc.
    Inventor: James C. Chen
  • Patent number: 7297326
    Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: November 20, 2007
    Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Lee E. Goldstein, Leo T. Chylack, Jr.
  • Patent number: 7268155
    Abstract: Conjugate molecules which include photosensitizer compositions conjugated to non-antibody non-affinity pair targeting moieties and methods of making and using such conjugates are described.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: September 11, 2007
    Assignee: The General Hospital Corporation
    Inventors: Tayyaba Hasan, Michael R. Hamblin, Nikos Soukos
  • Patent number: 7265100
    Abstract: The present invention refers to a process for the separation of regioisomeric mixtures of metal phthalocyanines of formula (I), to the regioisomers obtained by this process, and their use as phototherapeutic and photodiagnostic agents
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: September 4, 2007
    Assignee: L. Molteni & C. Dei Fratelli Alitti Societa' di Esercizio S.p.A.
    Inventors: Gabrio Roncucci, Francesca Giuntini, Donata Dei, Maria Paola De Filippis, Paolo Sarri, Marco Possenti, Valentina Paschetta, Giacomo Chiti
  • Patent number: 7255851
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: August 14, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 7244841
    Abstract: A compound of formula I: wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilizing solutions comprising a compound of the invention, and the use thereof, are also disclosed.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: July 17, 2007
    Assignees: Destiny Pharma Limited, Solvias AG
    Inventors: William Love, Derek Brundish, William Rhys-Williams, Xiang Dong Feng, Benoit Pugin
  • Patent number: 7198774
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: April 3, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 7192650
    Abstract: A photo-functional molecule element having, on a substrate, a porphyrin polymer containing covalently-fixed porphyrin units, and the method of preparing the same. The photo-functional molecule element may be used as a photoelectric conversion element such as an organic solar cell or a three-dimensional, non-linear organic material.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 20, 2007
    Assignee: Nara Institute of Science and Technology
    Inventors: Yoshiaki Kobuke, Akiharu Satake
  • Patent number: 7153956
    Abstract: The present invention provides an IR-absorbing dye of formula (I) or (II) wherein R10, R13, R20, R23, R30, R33, R40 and R43 are independently selected from a C1-12 alkyl group bearing a hydrophilic or hydrophilizable group; R11, R12, R21, R22, R31, R32, R41 and R42 are independently selected from H or a C1-30 hydrocarbyl group, or each of R11/R12, R21/R22, R31/R32, and R41/R42 are together joined to form a C3-30 hydrocarbylene group; M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), VO, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing intermolecular interactions; R3 is a selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: December 26, 2006
    Assignee: Silverbrook Research Pty Ltd
    Inventors: Simone Charlotte Vonwiller, Scott Matthew Starling, Damon Donald Ridley, Lachlan Everett Hall, Simon Fielder, Graciel Gonzaga, Kia Silverbrook, Paul Lapstun
  • Patent number: 7147840
    Abstract: A compound having the structural formula: where R is H or lower alkyl of 1 through 12 carbon atoms. In general, the compounds of the invention are 132-Oxo-bacteriopyropheophorbide—a carboxylic acid and C1–C12 alkyl esters thereof. A method for the preparation of the carboxylic acid compounds of the invention includes the step of reacting bacteriopyropheophorbide—a alkyl ester with lithium hydroxide tetrahydrofuran and water.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: December 12, 2006
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Andrei Kozyrev, Xiang Zheng
  • Patent number: 7148345
    Abstract: The present invention provides an IR-absorbing naphthalocyanine dye of formula (I): wherein M is selected from Ga(A1); A1 is an axial ligand selected from —OH, halogen (preferably Cl), —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R1 and R2 may be the same or different and are selected from hydrogen or C1-12 alkoxy (preferably C1-6 alkoxy); R3 is selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl, C1-12 alkoxy, C5-12 aryloxy or C5-12 arylalkoxy; W is a hydrophilic group; n1 is 0, 1, 2 or 3; n2 is 0, 1, 2 or 3; n3 is 0, 1, 2 or 3; n4 is 0, 1, 2 or 3; provided that at least one of n1, n2, n3 or n4 is greater than 0. Dyes of this type are especially suitable for use in netpage and Hyperlabel™ systems.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: December 12, 2006
    Assignee: Silverbrook Research Pty Ltd
    Inventors: Simone Charlotte Vonwiller, Scott Matthew Starling, Damon Donald Ridley, Lachlan Everett Hall, Simon Fielder, Sutharsiny Indusegaram, Kia Silverbrook, Paul Lapstun
  • Patent number: 7138103
    Abstract: The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the targetable constructs and bi-specific antibodies or antibody fragments, as well as methods for using them.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: November 21, 2006
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7138391
    Abstract: The present invention provides an IR-absorbing dye of formula (I) or (II): wherein Q1, Q2, Q3 and Q4 are the same or different and are independently selected from a C3-20 heteroarylene group comprising at least one N atom; M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), VO, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R3 is a selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl, C1-12 alkoxy, C5-12 aryloxy or C5-12 arylalkoxy. Dyes of this type are especially suitable for use in netpage and Hyperlabel systems.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: November 21, 2006
    Assignee: Silverbrook Research Pty Ltd
    Inventors: Simone Charlotte Vonwiller, Scott Matthew Starling, Damon Donald Ridley, Lachlan Everett Hall, Simon Fielder, Graciel Gonzaga, Kia Silverbrook, Paul Lapstun
  • Patent number: 7125542
    Abstract: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Joan W. Miller, Evangelos S. Gragoudas, Reem Z. Renno
  • Patent number: 7122076
    Abstract: The present invention provides an IR-absorbing naphthalocyanine dye of formula (I): wherein M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), Vo, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R1 and R2 are selected from H or C1-12alkoxy; R3 is selected from C1-12alkyl, C5-12aryl, C5-12arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12alkyl, C5-12aryl, C5-12arylalkyl, C1-12 alkoxy, C5-12aryloxy or C5-12arylalkoxy; W is a hydrophilic group; n1 is 0, 1, 2 or 3; n2 is 0, 1, 2 or 3; n3 is 0, 1, 2 or 3; n4 is 0, 1, 2 or 3; provided that at least one of n1, n2, n3 or n4 is greater than 0. Dyes of this type are especially suitable for use in netpage and Hyperlabel systems.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: October 17, 2006
    Assignee: Silverbrook Research Pty Ltd
    Inventors: Simone Charlotte Vonwiller, Scott Matthew Starling, Damon Donald Ridley, Lachlan Everett Hall, Simon Fielder, Sutharsiny Indusegaram, Kia Silverbrook, Paul Lapstun
  • Patent number: 7094866
    Abstract: A covalently linked linear porphyrin polymer represented by formula (1): wherein R represents an alkyl group or ?(wherein a, b and d independently represent H, an alkyl group or aryl group); X represents —O—, —S—, >NR101 (wherein R101 represents H or an alkyl group), —CH2— or a single bond; Y represents ?O, ?S, or 2H; m represents an integer of 0 to 4; n represents an integer of 0 to 6; Z represents a five- or six-membered, nitrogen-containing, coordinating hetero aromatic ring group; M represents an ion of metal selected from typical metals and transition metals; Q1 represents a single bond or a linear, divalent linking group; and p1 represents an integer of 2 or more.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: August 22, 2006
    Assignee: Nara Institute of Science and Technology
    Inventors: Yoshiaki Kobuke, Akiharu Satake
  • Patent number: 7087214
    Abstract: The invention relates to novel, water-soluble porphyrin platinum compounds of the tetraarylporphyrin platinum derivatives type or of the hematoporphyrin platinum derivatives type with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases. In particular, the compounds are suitable for photodynamic anti-tumor therapy.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: August 8, 2006
    Assignee: Zentaris GmbH
    Inventors: Karl Christian Bart, Guenther Bernhardt, Henri Brunner, Christian Lottner
  • Patent number: 7053210
    Abstract: A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1?-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e6, in the form of its trimethyl ester, with a base, followed by heating to give pyropheophorbide a, which is converted to HPPH by treatment with acid, followed by hexyl alcohol under basic conditions.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: May 30, 2006
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Thomas J. Dougherty, Alexander J. Pallenberg
  • Patent number: 7045117
    Abstract: Palladium-substituted Bacteriochlorophyll derivatives are administered to a subject suspected of having a tumor and the patient is then irradiated and the fluorescence of the suspected area is measured. A high fluorescence indicates a tumor site. A preferred derivative is Pd-Bacteriopheophorbide a.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: May 16, 2006
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Avigdor Scherz, Yoram Salomon, Alexander Brandis, Hugo Scheer
  • Patent number: 7030105
    Abstract: The invention provides a method for preparing glutathionylcobalamin (GluSCbl) which involves running the reaction in an aqueous solvent with a relatively small excess of glutathione, i.e. GluSH, specifically from one to less than four molar equivalents of GluSH. The formed GluSCbl is precipitated from the aqueous solvent, preferably by the addition of a precipitate inducing solvent. This provides GluSCbl in acceptable purity without the need for an additional chromatographic purification step. Additionally, it has been found that the reaction can be run to an acceptable level of purity by using very high concentrations of the reactants, i.e. around saturation concentrations for aquocobalamin. This has the advantage of eliminating the need for air-free conditions.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: April 18, 2006
    Assignee: Kent State University
    Inventors: Nicola E. Brasch, Ling Xia
  • Patent number: 7026347
    Abstract: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: April 11, 2006
    Assignee: CellGate, Inc.
    Inventors: Benjamin Frydman, Aldonia L. Valasinas, Venodhar K. Reddy, Hirak S. Basu, Aparajita Sarkar, Subhra Bhattacharya, Yu Wang, Laurence J. Marton, Andrei V. Blokhin
  • Patent number: 7022840
    Abstract: A porphyrin array exhibiting a large two-photon absorption property, and being linked with an acetylenic bond(s), represented by the following formulas: wherein R1 represents an alkyl or aryl group, M1 represents a metal ion capable of serving as a core metal and forming a coordinate bond with Im, M2 represents two protons or a metal ion incapable of forming a coordinate bond with Im, R2 and R3 represent a group selected from a porphyrin residue or porphyrin metal complex residue, a cyclic diimide residue, a dialkylviologen residue, a benzoquinone residue, an N-methylpyrrolidine-fullerene derivative residue and a ferrocene residue, Im is represented by Im1 or Im2: (R8 represents methyl or H), L1 represents —(—C?C—)m— (m=1 to 3); n represents an integer of 1 or more; R9 represents one of R1, R2, R3 and Im.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: April 4, 2006
    Assignee: Nara Institute of Science and Technology
    Inventors: Yoshiaki Kobuke, Kazuya Ogawa
  • Patent number: 7019132
    Abstract: The present invention is related to novel photopyrin compounds and the pharmaceutically acceptable salt thereof useful as an anticancer or photodynamic diagnostic agent by way of reproducing singlet state oxygen radical and the inventive compounds have superior advantages such as excellent photon yield to produce singlet oxygen, good physical stability and potent cell cytotoxicity to conventional photosensitizer. The present invention also provides a pharmaceutical composition comprising a novel photopyrin compound of formula (I) to (VII) or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating various cancers such as stomach cancer, liver cancer, lung cancer, cervical cancer and breast cancer in human or mammal together with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: March 28, 2006
    Assignee: Kostarworld Co., Ltd.
    Inventors: Nam-Tae Woo, Min-Suk Kang, Won-Young Lee, Chang-Hee Lee, Yong-Rok Kim, Dai-Woon Lee, Dong-Hoon Won, Si-Hwan Ko
  • Patent number: 7014839
    Abstract: The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: March 21, 2006
    Assignee: Amersham Health AS
    Inventors: Jo Klaveness, Bjorn Fuglaas, Pål Rongved, Edvin Johannesen, Paul Mark Henrichs, Wolfgang Hans Heinrich Gunther, Edward Richard Bacon, John Luke Toner, Gregory Lynn McIntire, Vinay C. Desai
  • Patent number: 7008742
    Abstract: A process for forming a cocrystalline mixture of titanyl phthalocyanine (TiOPc) and titanyl fluorophthalocyanine (TiOFPc) includes: dry milling a mixture of crude TiOPc and crude TiOFPc, thereby forming an amorphous pigment mixture of TiOPc and TiOFPc; and heating the amorphous pigment mixture at a temperature effective to form a cocrystalline composition comprising titanyl phthalocyanine (TiOPc) and titanyl fluorophthalocyanine (TiOFPc), the cocrystalline composition being characterized by an X-ray diffraction spectrum exhibiting intensity peaks at 7.2°, 12.9°, 16.3°, 22.3°, 24.6°, 26.2°, and 28.8° with respect to X-rays of Cu K?at a wavelength of 1.54 1 ? of the Bragg angle 2?.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: March 7, 2006
    Assignee: Eastman Kodak Company
    Inventor: Michel F. Molaire
  • Patent number: 7008937
    Abstract: The present invention provides a class of porphyrins and metal chelated porphyrins for use as inhibitors of heme iron uptake. The porphyrin/metal chelated porphyrin molecules of the invention are tetra-positively charged porphyrins based on meso-tetra(4-pyridyl)porphines. Several such agents are shown herein to cause inhibition of iron uptake in vivo and in vitro. The invention further provides therapeutic compositions including the porphyrins and/or metalloporphyrins of the invention. In addition, methods of inhibition of heme iron uptake in vivo are taught, as well as methods of treatment of diseases characterized by iron-overload. These methods include the administration of a porphyrin or metalloporphyrin in a therapeutic composition of the invention to prevent uptake of heme iron, thus preventing replenishment of a patient's iron stores.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: March 7, 2006
    Assignee: Frontier Scientific, Inc.
    Inventor: Jerry C. Bommer
  • Patent number: 7005519
    Abstract: This invention relates to a method of preparing a compound of formula (I): The method includes reacting one or more compounds of formula (II): in the presence of a base and a halogenating agent. In formulas (I) and (II) above, each A, independently, is aryl or heteroaryl; each n, independently, is 0–3; and each R1, independently, is C1–C10 alkyl, C3–C20 cycloalkyl, C3–C20 heterocycloalkyl, aryl, heteroaryl, halo, cyano, nitro, ORa, NRaRb, SiRaRbRc, COORa, OC(O)Ra, C(O)NRaRb, N(Ra)—C(O)Rb, or SO3Ra; wherein each of Ra, Rb, and Rc, independently, is H, C1–C10 alkyl, C3–C20 cycloalkyl, C3–C20 heterocycloalkyl, aryl, or heteroaryl; thereby producing the compound of formula (I) in a one-pot reaction. This invention also relates to the compounds prepared by the method described above.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 28, 2006
    Assignee: Academia Sinica
    Inventors: Chin-Ti Chen, Hsiu-Chih Yeh
  • Patent number: 7005518
    Abstract: Fluorescent dyes are disclosed which are useful as reporter groups for labeling biomolecules. The silicon phthalocyanine dyes disclosed are preferably water soluble, isomericly pure, possess high quantum yield, and are useful in bioassays.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: February 28, 2006
    Assignee: Li-Cor, Inc.
    Inventors: Xinzhan Peng, Daniel R. Draney, Jiyan Chen
  • Patent number: 7001588
    Abstract: Expanded porphyrin comprising substitutions for at least two NH groups by S, Se or Te are non-photoactive and are selective for binding G-quadruplexes characteristic of the c-MYC control region. Accordingly, these expanded porphyrins are useful to modulate the expression of genes controlled by the formation of c-MYC type G-quadruplexes, such as c-MYC itself.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: February 21, 2006
    Assignee: Cylene Pharmaceuticals
    Inventor: Laurence H. Hurley
  • Patent number: 6995260
    Abstract: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing 5, 10, 15, 20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing tetraphenyl porphyrin compounds to methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: February 7, 2006
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Haitao Wu, Michiko Miura
  • Patent number: 6989443
    Abstract: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing 5, 10, 15, 20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head, neck, and surrounding tissue. The invention is also directed to using these carborane-containing tetraphenyl porphyrin compounds to methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: January 24, 2006
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Haitao Wu, Michiko Miura
  • Patent number: 6982090
    Abstract: An improved punctum plug is more easily visualized when positioned within a punctual canal of a recipient. The body of the plug features an outwardly exposed surface when properly positioned, and a substance causing at least the outwardly exposed surface to contrast with surrounding tissue, such that the use of the substance causes the plug to be more easily visualized than if the substance were not present. The substance, which may be disposed on the outwardly exposed surface or within the body of the plug, may include a saturated coloration, or may be phosphorescent, fluorescent or otherwise operative to reflect or re-radiate light to assist in visualization. For example, the substance may include an organic or inorganic phosphor or fluorescent material, reflective beads, quantum dots, a dye or pigment. Such reflection or re-radiation may occur at the same or different wavelength(s) compared to the illumination wavelength(s), whether or not either or both are within the visible part of the spectrum.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: January 3, 2006
    Inventor: Donald E. Gillespie
  • Patent number: 6977075
    Abstract: The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: December 20, 2005
    Assignee: The General Hospital Corporation
    Inventors: Tayyaba Hasan, Jerome Gross, Gerard J. Nau
  • Patent number: 6953570
    Abstract: A method of increasing the multi-photon absorption cross-section of a porphyrin-based photosensitizer by attaching at least one TPA-chromophore at the meso- or beta-positions of a porphyrin structure of the porphyrin-based photosensitizer, and at least one intersystem crossing enhancing substituent to meso- or beta-positions of a porphyrin structure of the porphyrin-based photosensitizer, to thereby increase multi-photon absorption cross-section of the porphyrin-based photosensitizer to at least about 30 GM units at about its maximum wavelength for two-photon absorption. The TPA-chromophore is selected from a group of ?-conjugated structures. The resulting porphyrin-based photosensitizer absorbs two photons of radiation in the range of about 700 nm to about 1300 nm.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: October 11, 2005
    Assignee: Montana State University
    Inventors: Eric Nickel, Charles W. Spangler, Aleksander Rebane
  • Patent number: 6939533
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: September 6, 2005
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 6923951
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: August 2, 2005
    Assignee: Board of Trustees of the Leland Stanford University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 6916462
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: July 12, 2005
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron